Eli Lilly (NYSE: LLY) has officially entered into a definitive agreement to acquire Orna Therapeutics in a deal valued at up to $2.4 billion in cash. This strategic move, announced on February 9, 2026, marks a significant expansion for the pharmaceutical giant as it diversifies its portfolio beyond its dominant obesity and diabetes treatments. The acquisition targets Orna’s proprietary "circular RNA" platform. Unlike traditional linear mRNA, circular RNA is engineered for greater stability and durability within the body. This technology enables a patient’s own cells to act as a "bioreactor," generating therapeutic proteins in situ. By reprogramming cells internally, Lilly aims to bypass the costly and logistically intensive process of extracting, modifying, and re-infusing cells required by current CAR-T therapies. Market reaction has been positive, with Eli Lilly shares rising over 2% in early trading following the news. As of today, Lilly maintains a massive market capitalization of approximately $1.0 trillion, with the stock trading near $1,080. The company reported a 44.7% revenue increase over the past year, reaching $65.18 billion, providing ample liquidity for this $2.4 billion cash investment. The focal point of the deal is Orna’s lead program, ORN-252. This is a clinical trial-ready in vivo CAR-T therapy designed to treat B cell-driven autoimmune diseases. By utilizing lipid nanoparticles (LNPs) to deliver circular RNA directly to the immune system, the treatment could offer a "redosable" and "off-the-shelf" solution for patients who currently have limited options. This acquisition arrives as the broader RNA therapeutics market is projected to grow from $27.1 billion in 2025 to over $103 billion by 2035. The shift toward in vivo engineering is viewed by analysts as the "next generation" of cell therapy, potentially reducing the extreme price tags and complex manufacturing bottlenecks that have hindered the adoption of first-generation gene therapies. For Eli Lilly, the deal represents a calculated bet on immunology and oncology. While the company continues to see surging demand for its GLP-1 drugs, Mounjaro and Zepbound, this $2.4 billion commitment secures a leading position in the emerging field of programmable medicines. The transaction includes an immediate upfront payment and subsequent milestone-based rewards as Orna’s pipeline advances through clinical stages.